CDDF Annual Conference
Changing paradigms to accelerate oncology drug development
5 – 7 February 2024, Hybrid Conference
Recordings
SESSION 1: REAL WORLD EVIDENCE
Regulatory Perspective on Opportunities for Oncology RWE – Donna Rivera (FDA, US)
Regulatory Perspective – Francesco Pignatti (EMA, NL)
Payers’ Perspective – Carole Longson (Carole Longson Consultant, UK)
Project Darwin EU – Peter Rijnbeek (Erasmus Medical Center, NL)
Academic Perspective – Peter Mol (University Medical Center Groningen, NL)
Project Optima – James N’Dow (University of Aberdeen, UK)
SESSION 2: REFLECTIONS ON CDDF WORKSHOPS AND JOINT ACTIVITIES IN 2023
SESSION 3: DECENTRALISED CARE AND TRIALS
Learning from COVID-19 – academic perspective – Richard Sullivan (King’s College London, UK)
Regulatory Perspective (FDA) – Timil Patel (FDA, US)
How to run a decentralized clinical trials – industry perspective – Luis Garcia-Gancedo (AstraZeneca, UK) – did not consent
Patient Perspective – Hans Scheurer (Myeloma Patients Europe, NL)